Results 31 to 40 of about 2,285,787 (260)

Evaluation of CAR-T cell cytotoxicity against a prostate carcinoma model

Учёные записки Казанского университета: Серия Естественные науки, 2022
In recent years, a new promising application of adoptive cell therapy (ACT) has been enabled by the development of technologies and the successful clinical use of T cells with a chimeric antigen receptor (CAR-T) for treating patients with malignant B ...
A.Kh. Valiullina, E.A. Zmievskaya, A.R. Rakhmatullina, M.N. Zhuravleva, E.E. Garanina, R.R. Miftakhova, A.V. Petukhov, A.A. Rizvanov, E.R. Bulatov   +8 more
doaj   +1 more source

Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis

Journal of Immunology Research, 2021
CD47 is a cell surface glycoprotein molecule, belonging to the immunoglobulin superfamily, binding to various proteins including integrins, thrombospondin-1, and signal regulatory protein α (SIRPα).
Huyen Thi La, Dao Bich Thi Tran, Hai Manh Tran, Linh Trong Nguyen   +3 more
doaj   +1 more source

Chimeric Antigen Receptor—Macrophages in Pancreatic Cancer: Promise, Pitfalls, and the Path Ahead

Frontiers in Bioscience-Elite
Chimeric antigen receptor–engineered macrophages (CAR-Ms) are emerging as a transformative frontier in immunotherapy and represent a promising strategy for pancreatic cancer.
Palloma Porto Almeida, Leandro Martins de Freitas   +1 more
doaj   +1 more source

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers

Nature Communications, 2022
Antigen escape represents a potential drawback of chimeric antigen receptor T cell (CAR-T) therapy targeting a single tumor-associated antigen. To reduce the risk of antigen escape, here the authors report the design and characterization of a BAFF ligand
Derek P. Wong, Nand K. Roy, Keman Zhang, Anusha Anukanth, Abhishek Asthana, Nicole J. Shirkey-Son, Samantha Dunmire, Bryan J. Jones, Walker S. Lahr, Beau R. Webber, Branden S. Moriarity, Paolo Caimi, Reshmi Parameswaran   +12 more
doaj   +1 more source

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy

Frontiers in Immunology, 2023
Advancements in chimeric antigen receptor engineered T-cell (CAR-T) therapy have revolutionized treatment for several cancer types over the past decade. Despite this success, obstacles including the high price tag, manufacturing complexity, and treatment-
Marisa K. Kilgour, Donald J. Bastin, Seung-Hwan Lee, Seung-Hwan Lee, Michele Ardolino, Michele Ardolino, Michele Ardolino, Scott McComb, Scott McComb, Scott McComb, Alissa Visram   +10 more
doaj   +1 more source

Oligoclonal expansions of CD8(+) T cells in chronic HIV infection are antigen specific [PDF]

, 1998
Acute HIV infection is associated with a vigorous immune response characterized by the proliferation of selected T cell receptor V beta (BV)-expressing CD8(+) T cells.
Ogg, GS, Christopher A. O'Callaghan, Philip J.R. Goulder, O'Callaghan, CA, Allen, RL, Anthony Kelleher, Andy K. Sewell, Rowland-Jones, Sarah, Jamie D.K. Wilson, Kelleher, A, Mcmichael, Andrew, Goulder, PJ, Andrew J. McMichael, O'Callaghan, Christopher, Graham S. Ogg, Rachel L. Allen, Rowland-Jones, SL, Callan, MF, Wilson, JD, Sarah L. Rowland-Jones, Margaret F.C. Callan, Sewell, AK, McMichael, AJ   +22 more
core   +1 more source

Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity

, 2023
Ligand-induced receptor dimerization or oligomerization is a widespread mechanism for ensuring communication specificity, safeguarding receptor activation, and facilitating amplification of signal transduction across the cellular membrane.
Jia-Chen Cui, Sai-Juan Chen, Yi-Zhu Lyu, Guang-Xiang Huang, Jie Xu, Xiao-Hu Fan, Kai-Wen Liu, Bing Zhang, Shuo Chen, Jian-Qing Mi, Xiu-Na Yang, Cheng-Lin Liu, Shuang-Shuang Yang, Yan Sun, Zhu Chen, Na Li   +15 more
core   +1 more source

Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013–2025

Human Vaccines & Immunotherapeutics
CAR-T cell therapy has dramatically changed the treatment paradigm for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, there is a notable paucity of comprehensive bibliometric analyses within this specialized domain.
Tiantian Zhang, Shenyu Wang, Xin Li, Xiaohong Li, Yamei Wu   +4 more
doaj   +1 more source

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

, 2019
B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease.
Saiko Kurosawa, Katsuaki Imaizumi, Shinichi Makita, Kensei Tobinai   +3 more
core   +1 more source

Chimeric Antigen Receptor T-Cell Revolution Remodeling Immunity to Conquer Autoimmune Disease

Research
Chimeric antigen receptor T (CAR-T) cell therapy, a groundbreaking technology in tumor immunotherapy, has demonstrated unprecedented potential in the field of autoimmune diseases in recent years.
Wenxia Shao, Jiayu Liu, Ming Sun, Daojun Yu   +3 more
doaj   +1 more source